The Healthcare sector is made up of devices and systems that support healthcare organizations such as hospitals, doctor’s offices, surgical centers, and more. Healthcare technologies range from equipment like imaging machinery and robotic surgical assistants to patient recordkeeping applications and scheduling support. Register today to discover how Forge can help you buy and sell private shares.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids | $ Total Asks | # Bids | # Asks | Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| Odyssey Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $413MM | Series D | 9/10/2025 | $213MM | $530.29MM | $1.50 | Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG, Wedbush Healthcare Partners | |||||
| Shoreline Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $186MM | Series B | 11/2/2021 | $140MM | $527.99MM | $10.07 | Ally Bridge Group, Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, Superstring, BVF Partners, Commodore Capital, Cormorant Asset Management, Janus Henderson Investors, Kite, Stork Capital, Wedbush Healthcare Partners | |||||
| Rad AI | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $163.36MM | Series C | 5/20/2025 | $80.9MM | $527.53MM | $22.51 | Transformation Capital, Khosla Ventures, World Innovation Lab, UP2398, Kickstart, OCV Partners, Cone Health, Advocate Health, Memorial Hermann Health System, Corewell Health, Atlantic Health System | |||||
| R-Zero | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $173.45MM | Series C | 2/16/2023 | $105MM | $526.86MM | $14.13 | BMO Financial Group, Qualcomm Ventures, Upfront Ventures, DBL Partners, World Innovation Lab, Mayo Clinic, Bedrock Capital, SOSV, John Doerr | |||||
| Latigo Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $287.9MM | Series B | 3/17/2025 | $150MM | $525.73MM | $1.57 | Blue Owl Capital, Deep Track Capital, Access Biotechnology, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, Kern Capital, Westlake Village BioPartners, Foresite Capital, 5AM Ventures, Alexandria Venture Investments | |||||
| Capstan Therapeutics | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $845MM | Series B | 3/20/2024 | $175MM | $525.33MM | $3.37 | RA Capital Management, Forbion, Johnson & Johnson, Mubadala Capital, Perceptive Advisors, Sofinnova Investments, Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly, Bayer, Novartis Venture Fund, OrbiMed, Pfizer Ventures, Polaris Partners, Vida Ventures | |||||
| Sionna Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $331.32MM | Series C | 3/6/2024 | $181.86MM | $523.7MM | $9.76 | Enavate Sciences, Viking Global Investors, Perceptive Advisors, RA Capital, TPG, Atlas Venture, Cystic Fibrosis Foundation, T. Rowe Price, Qatar Investment Authority, OrbiMed | |||||
| Cellarity | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $435.63MM | Series D | 12/23/2024 | $196.06MM | $517.83MM | $3.60 | Undisclosed Investors | |||||
| Omniome | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $153.29MM | Series C | 1/9/2020 | $60MM | $511MM | $4.17 | Madrone Capital Partners, ARCH Venture Partners, Decheng Capital, Domain Associates, Biomatics Capital Partners, Altitude Life Science Ventures, Nan Fung Life Sciences | |||||
| Obsidian Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $325.04MM | Series C | 4/3/2024 | $160.5MM | $507.38MM | $1.90 | Wellington Management, Foresite Capital, Janus Henderson Investors, Novo Holdings, Paradigm BioCapital, RTW Investments, T. Rowe Price Associates, Woodline Partners, Atlas Venture, Blue Owl Capital, Bristol Myers Squibb, Deep Track Capital, Logos Capital, RA Capital Management, TCG Crossover Management, Samsara, Surveyor Capital | |||||
| Rivus Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $224.04MM | Series B-2 | 1/16/2025 | $122.98MM | $506.82MM | $4.76 | RA Capital Management, Bain Capital, BB Biotech AG, Longitutde Capital, Medicxi, RxCapital | |||||
| Workit Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $108.14MM | Series C | 10/22/2021 | $88MM | $506.42MM | $11.02 | Insight Partners, CVS Health Ventures, FirstMark Capital, BCBS Venture Fund, 3L Capital | |||||
| Paradigm Health | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $281MM | Series B-1 | 12/4/2025 | $57.73MM | $505.1MM | $1.00 | ARCH Venture Partners, DFJ Growth, F-Prime Capital, General Catalyst, GV, Lux Capital, Mubadala Capital, BrightEdge | |||||
| Profluent | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $150MM | Series B | 11/19/2025 | $106MM | $502.78MM | $34.07 | Altimeter Capital, Bezos Expeditions, Spark Capital, Insight Partners, Air Street Capital | |||||
| GATC Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $4.04MM | Series Seed | 7/11/2023 | $4.04MM | $500MM | $5.60 | Undisclosed Investors | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.